Third-generation cephalosporin (anti-pseudomonal)
Ceftazidime
Brand names: Fortum
Adult dose
Dose: 1–2g IV q8h (severe: 2g q8h)
Route: IV / IM
Frequency: q8h
Clinical pearls
- BSAC: febrile neutropenia, CF exacerbations (Pseudomonas), nosocomial pneumonia
- UKHSA AMR — preserve
- Renal dose adjustment essential
Contraindications
- Severe beta-lactam hypersensitivity
Side effects
- GI upset
- Hypersensitivity
- C. difficile
- Encephalopathy (renal impairment)
- Eosinophilia
Interactions
- Aminoglycosides
- Probenecid
Monitoring
- FBC
- Renal
- C. diff
- Mental state
Reference: BNF; BSAC; UKHSA AMR; CF Trust; https://bnf.nice.org.uk/drugs/ceftazidime/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023